Published in Medical Devices and Surgical Technology Week, February 13th, 2005
In a recent study, surgeons in the United States conducted a "retrospective analysis of a new treatment modality, intra-arterial administration of Yttrium-90 TheraSphere, for unresectable hepatocellular carcinoma (HCC)."
"Patients with HCC not amenable to surgical treatment who had satisfactory physiological function without comorbid disease or significant pulmonary shunting were eligible for treatment," noted M.D. Liu and coauthors at the University of California-Irvine Medical Center. "Patients were categorized into complete, partial, or no response based...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week